Protein kinase C and cancer: What we know and what we do not

Oncogene

Volumn 33, Issue 45, 2014, Pages 5225-5237

  Garg, R ^a   Benedetti, L G ^a   Abera, M B ^a   Wang, H ^a   Abba, M ^b   Kazanietz, M G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Animal models; Apoptosis; Metastasis; Protein kinase C (PKC); Survival; Tumorigenesis

Indexed keywords

PROTEIN KINASE C; ISOENZYME;

APOPTOSIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASM; MELANOMA; METASTASIS; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PRKCB GENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; NEOPLASMS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 85027928647     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.524     Document Type: Review

References (244)

1. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 1983; 258: 11442–11445.
2. Leach KL, James ML, Blumberg PM. Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc Natl Acad Sci USA 1983; 80: 4208–4212.
3. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281–294.
4. Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 2007; 67: 8828–8838.
5. Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007; 67: 6053–6063.
6. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, DiGiovanni J et al. Transgenic overexpression of PKCepsilon in the mouse prostate induces preneoplastic lesions. Cell Cycle 2011; 10: 268–277.
7. Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65: 8366–8371.
8. Wu-Zhang AX, Newton AC. Protein kinase C pharmacology: refining the toolbox. Biochem J 2013; 452: 195–209.
9. Schleifenbaum A, Stier G, Gasch A, Sattler M, Schultz C. Genetically encoded FRET probe for PKC activity based on pleckstrin. J Am Chem Soc 2004; 126: 11786–11787.
10. Chen CA, Yeh RH, Yan X, Lawrence DS. Biosensors of protein kinase action: from in vitro assays to living cells. Biochim Biophys Acta 2004; 1697: 39–51.
11. Gallegos LL, Kunkel MT, Newton AC. Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem 2006; 281: 30947–30956.
12. Gallegos LL, Newton AC. Genetically encoded fluorescent reporters to visualize protein kinase C activation in live cells. Methods Mol Biol 2011; 756: 295–310.
13. DeVries TA, Neville MC, Reyland ME. Nuclear import of PKCdelta is required for apoptosis: identification of a novel nuclear import sequence. Embo J 2002; 21: 6050–6060.
14. Wang H, Kazanietz MG. p23/Tmp21 differentially targets the Rac-GAP beta2-chimaerin and protein kinase C via their C1 domains. Mol Biol Cell 2010; 21: 1398–1408.
15. Jaken S, Parker PJ. Protein kinase C binding partners. Bioessays 2000; 22: 245–254.
16. Wang H, Xiao L, Kazanietz MG. p23/Tmp21 associates with protein kinase Cdelta (PKCdelta) and modulates its apoptotic function. J Biol Chem 2011; 286: 15821–15831.
17. Dai CM, Zhou XF, Zhang YL, Liu SG, Zhang J. Synthesis by precipitation polymerization of molecularly imprinted polymer for the selective extraction of diclofenac from water samples. J Hazard Mater 2011; 198: 175–181.
18. Cameron AJ, Procyk KJ, Leitges M, Parker PJ. PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer 2008; 123: 769–779.
19. Haughian JM, Reno EM, Thorne AM, Bradford AP. Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 2009; 125: 2556–2564.
20. Nakagawa S, Fujii T, Yokoyama G, Kazanietz MG, Yamana H, Shirouzu K. Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Calpha and extracellular signal-regulated kinase mitogen-activated protein kinase. Mol Carcinog 2003; 38: 106–116.
21. Kong C, Zhu Y, Liu D, Yu M, Li S, Li Z et al. Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology 2005; 65: 1228–1232.
22. Stewart JR, O’Brian CA. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 2004; 22: 107–117.
23. Suga K, Sugimoto I, Ito H, Hashimoto E. Down-regulation of protein kinase C-alpha detected in human colorectal cancer. Biochem Mol Biol Int 1998; 44: 523–528.
24. von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G et al. MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 2012; 180: 1787–1797.
25. Baltuch GH, Dooley NP, Rostworowski KM, Villemure JG, Yong VW. Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 1995; 24: 241–250.
26. Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G et al. Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001; 61: 4612–4619.
27. Blackburn RV, Galoforo SS, Berns CM, Motwani NM, Corry PM, Lee YJ. Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer 1998; 82: 1137–1145.
28. Mut M, Amos S, Hussaini IM. PKC alpha phosphorylates cytosolic NF-kappaB/p65 and PKC delta delays nuclear translocation of NF-kappaB/p65 in U1242 glioblastoma cells. Turk Neurosurg 2010; 20: 277–285.
29. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24: 1428–1434.
30. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ et al. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 2004; 100: 321–326.
31. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol 2005; 7: 32–40.
32. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 1994; 45: 1207–1214.
33. Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extra-cellular signal-regulated kinase pathway. Cancer Res 2004; 64: 3629–3637.
34. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995; 95: 1906–1915.
35. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000; 83: 782–791.
36. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 2001; 7: 3156–3165.
37. Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X et al. Crosstalk between PKCalpha and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis 2013; 2: e60.
38. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007; 60: 1216–1221.
39. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 2003; 88: 1400–1402.
40. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010; 9: 76.
41. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006; 25: 3286–3295.
42. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993; 268: 9194–9197.
43. Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst 1994; 86: 1145–1151.
44. Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS. PKCalpha and ERbeta are associated with triple-negative breast cancers in African American and Caucasian patients. Int J Breast Cancer 2012; 2012: 740353.
45. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F et al. Protein Kinase C alpha Is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 2013; 24: 347–364.
46. Oliva JL, Caino MC, Senderowicz AM, Kazanietz MG. S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J Biol Chem 2008; 283: 5466–5476.
47. Hizli AA, Black AR, Pysz MA, Black JD. Protein kinase C alpha signaling inhibits cyclin D1 translation in intestinal epithelial cells. J Biol Chem 2006; 281: 14596–14603.
48. Frey MR, Clark JA, Leontieva O, Uronis JM, Black AR, Black JD. Protein kinase C signaling mediates a program of cell cycle withdrawal in the intestinal epithelium. J Cell Biol 2000; 151: 763–778.
49. Guan L, Song K, Pysz MA, Curry KJ, Hizli AA, Danielpour D et al. Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells. J Biol Chem 2007; 282: 14213–14225.
50. Gwak J, Jung SJ, Kang DI, Kim EY, Kim DE, Chung YH et al. Stimulation of protein kinase C-alpha suppresses colon cancer cell proliferation by down-regulation of beta-catenin. J Cell Mol Med 2009; 13: 2171–2180.
51. Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim HY et al. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol Cell 2010; 37: 183–195.
52. Gwak J, Lee JH, Chung YH, Song GY, Oh S. Small molecule-based promotion of PKCalpha-mediated beta-catenin degradation suppresses the proliferation of CRT-positive cancer cells. PLoS One 2012; 7: e46697.
53. Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D et al. Anew mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium. J Cell Sci 2009; 122: 2191–2196.
54. Oster H, Leitges M. Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/ þ mice. Cancer Res 2006; 66: 6955–6963.
55. Pysz MA, Leontieva OV, Bateman NW, Uronis JM, Curry KJ, Threadgill DW et al. PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. Exp Cell Res 2009; 315: 1415–1428.
56. Hara T, Matsumura S, Hakuno F, Takahashi S, Chida K. PKCalpha suppresses 7,12-dimethylbenz[a]anthracene-induced skin tumor formation. Anticancer Res 2012; 32: 3097–3101.
57. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33753–33762.
58. Garcia-Bermejo ML, Leskow FC, Fujii T, Wang Q, Blumberg PM, Ohba M et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCalpha. J Biol Chem 2002; 277: 645–655.
59. Truman JP, Rotenberg SA, Kang JH, Lerman G, Fuks Z, Kolesnick R et al. PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo. Cancer Biol Ther 2009; 8: 54–63.
60. Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR et al. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis. Oncogene 2013; 33: 2134–2144.
61. Akakura S, Nochajski P, Gao L, Sotomayor P, Matsui S, Gelman IH. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle 2010; 9: 4656–4665.
62. Hao F, Pysz MA, Curry KJ, Haas KN, Seedhouse SJ, Black AR et al. Protein kinase Calpha signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium. J Biol Chem 2011; 286: 18104–18117.
63. Yang MY, Hsu LS, Peng CH, Shi YS, Wu CH, Wang CJ. Polyphenol-rich extracts from Solanum nigrum attenuated PKC alpha-mediated migration and invasion of hepatocellular carcinoma cells. J Agric Food Chem 2010; 58: 5806–5814.
64. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008; 27: 1273–1280.
65. Lin CW, Shen SC, Chien CC, Yang LY, Shia LT, Chen YC. 12-O-tetra-decanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCalpha/ERK/NF-kappaB-dependent MMP-9 expression. J Cell Physiol 2010; 225: 472–481.
66. Shi MD, Shih YW, Lee YS, Cheng YF, Tsai LY. Suppression of 12-O-tetra-decanoylphorbol-13-acetate-induced MCF-7 breast adenocarcinoma cells invasion/migration by alpha-tomatine through activating PKCalpha/ERK/ NF-kappaB-dependent MMP-2/MMP-9 expressions. Cell Biochem Biophys 2013; 66: 161–174.
67. Byers HR, Boissel SJ, Tu C, Park HY. RNAi-mediated knockdown of protein kinase C-alpha inhibits cell migration in MM-RU human metastatic melanoma cell line. Melanoma Res 2010; 20: 171–178.
68. Wu TT, Hsieh YH, Hsieh YS, Liu JY. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem 2008; 103: 9–20.
69. Kim S, Han J, Lee SK, Choi MY, Kim J, Lee J et al. Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-alpha in breast cancer cells. J Surg Res 2012; 176: e21–e29.
70. Lahn M, Kohler G, Sundell K, Su C, Li S, Paterson BM et al. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004; 67: 1–10.
71. Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D. Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 2011; 30: 323–333.
72. Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R et al. Role of cycloox-ygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem 2003; 278: 11167–11174.
73. Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl DM et al. Cen-trosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 2008; 68: 6831–6839.
74. Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A et al. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol 2006; 85: 597–603.
75. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002; 20: 241–251.
76. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 2001; 7: 634–640.
77. Blobe GC, Stribling DS, Fabbro D, Stabel S, Hannun YA. Protein kinase C beta II specifically binds to and is activated by F-actin. J Biol Chem 1996; 271: 15823–15830.
78. Gokmen-Polar Y, Fields AP. Mapping of a molecular determinant for protein kinase C betaII isozyme function. J Biol Chem 1998; 273: 20261–20266.
79. Stebbins EG, Mochly-Rosen D. Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C. J Biol Chem 2001; 276: 29644–29650.
80. Craven PA, DeRubertis FR. Alterations in protein kinase C in 1,2-dimethylhy-drazine induced colonic carcinogenesis. Cancer Res 1992; 52: 2216–2221.
81. Davidson LA, Aymond CM, Jiang YH, Turner ND, Lupton JR, Chapkin RS. Non-invasive detection of fecal protein kinase C betaII and zeta messenger RNA: putative biomarkers for colon cancer. Carcinogenesis 1998; 19: 253–257.
82. Davidson D, Viallet J, Veillette A. Unique catalytic properties dictate the enhanced function of p59fynT, the hemopoietic cell-specific isoform of the Fyn tyrosine protein kinase, in T cells. Mol Cell Biol 1994; 14: 4554–4564.
83. Spindler KL, Lindebjerg J, Lahn M, Kjaer-Frifeldt S, Jakobsen A. Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. Int J Colorectal Dis 2009; 24: 641–645.
84. Sauma S, Yan Z, Ohno S, Friedman E. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ 1996; 7: 587–594.
85. Lee H, Ghose-Dastidar J, Winawer S, Friedman E. Signal transduction through extracellular signal-regulated kinase-like pp57 blocked in differentiated cells having low protein kinase C beta activity. J Biol Chem 1993; 268: 5255–5263.
86. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyper-proliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999; 145: 699–711.
87. Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, Fields AP et al. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 2008; 122: 2462–2470.
88. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 2004; 279: 22118–22123.
89. Goldstein DR, Cacace AM, Weinstein IB. Overexpression of protein kinase C beta 1 in the SW480 colon cancer cell line causes growth suppression. Carcinogenesis 1995; 16: 1121–1126.
90. Cesaro P, Raiteri E, Demoz M, Castino R, Baccino FM, Bonelli G et al. Expression of protein kinase C beta1 confers resistance to TNFalpha-and paclitaxel-induced apoptosis in HT-29 colon carcinoma cells. Int J Cancer 2001; 93: 179–184.
91. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 2010; 464: 792–796.
92. Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F et al. Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 99: 473–480.
93. Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res 2006; 66: 11399–11408.
94. Manni A, Buckwalter E, Etindi R, Kunselman S, Rossini A, Mauger D et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and-beta overexpression. Cell Growth Differ 1996; 7: 1187–1198.
95. Grossoni VC, Todaro LB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ. Opposite effects of protein kinase C beta1 (PKCbeta1) and PKCepsilon in the metastatic potential of a breast cancer murine model. Breast Cancer Res Treat 2009; 118: 469–480.
96. Hanauske AR, Oberschmidt O, Hanauske-Abel H, Lahn MM, Eismann U. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments. Invest New Drugs 2007; 25: 205–210.
97. Jasinski P, Terai K, Zwolak P, Dudek AZ. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer 2008; 44: 1315–1322.
98. Gokmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat 2010; 124: 327–335.
99. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemo Pharmacol 2001; 48: 473–480.
100. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008; 99: 750–759.
101. Willey CD, Xiao D, Tu T, Kim KW, Moretti L, Niermann KJ et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010; 77: 1518–1526.
102. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462–7469.
103. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 2010; 12: 181–189.
104. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377–1384.
105. Li S, Phong M, Lahn M, Brail L, Sutton S, Lin BK et al. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol Direct 2007; 2: 8.
106. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006; 126: 1641–1647.
107. Civallero M, Cosenza M, Grisendi G, Marcheselli L, Todoerti K, Sacchi S. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 2010; 51: 671–679.
108. Civallero M, Cosenza M, Neri A, Bari A. Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. Hematol Oncol 2011; 29: 154–156.
109. Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma 2011; 52: 1474–1480.
110. Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013; 23: 77–92.
111. Irie K, Yanagita RC, Nakagawa Y. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cdelta. Med Res Rev 2012; 32: 518–535.
112. Yonezawa T, Kurata R, Kimura M, Inoko H. PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq 2009; 3: 96–101.
113. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem 2009; 9: 498–509.
114. Zhao M, Xia L, Chen GQ. Protein kinase cdelta in apoptosis: a brief overview. Arch Immunol Ther Exp (Warsz) 2012; 60: 361–372.
115. Basu A, Pal D. Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. Scientific World J 2010; 10: 2272–2284.
116. Fujii T, Garcia-Bermejo ML, Bernabo JL, Caamano J, Ohba M, Kuroki T et al. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. J Biol Chem 2000; 275: 7574–7582.
117. Xiao L, Eto M, Kazanietz MG. ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK. J Biol Chem 2009; 284: 29365–29375.
118. Gonzalez-Guerrico AM, Kazanietz MG. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J Biol Chem 2005; 280: 38982–38991.
119. Xiao L, Caino MC, von Burstin VA, Oliva JL, Kazanietz MG. Phorbol ester-induced apoptosis and senescence in cancer cell models. Methods Enzymol 2008; 446: 123–139.
120. Xiao L, Gonzalez-Guerrico A, Kazanietz MG. PKC-mediated secretion of death factors in LNCaP prostate cancer cells is regulated by androgens. Mol Carcinog 2009; 48: 187–195.
121. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG et al. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268: 6090–6096.
122. Gavrielides MV, Frijhoff AF, Conti CJ, Kazanietz MG. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr Drug Targets 2004; 5: 431–443.
123. Nakagawa M, Oliva JL, Kothapalli D, Fournier A, Assoian RK, Kazanietz MG. Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21. J Biol Chem 2005; 280: 33926–33934.
124. Santiago-Walker AE, Fikaris AJ, Kao GD, Brown EJ, Kazanietz MG, Meinkoth JL. Protein kinase C delta stimulates apoptosis by initiating G1 phase cell cycle progression and S phase arrest. J Biol Chem 2005; 280: 32107–32114.
125. Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ. Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog 2007; 46: 381–390.
126. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR, Bradford AP. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol 2008; 39: 21–29.
127. Fukase N, Kawamoto T, Kishimoto K, Hara H, Okada Y, Onishi Y et al. Protein kinase Cdelta in tumorigenesis of human malignant fibrous histiocytoma. Oncology Reports 2011; 26: 1221–1226.
128. Yadav V, Yanez NC, Fenton SE, Denning MF. Loss of protein kinase C delta gene expression in human squamous cell carcinomas: a laser capture microdissection study. Am J Pathol 2010; 176: 1091–1096.
129. Tsai JH, Hsieh YS, Kuo SJ, Chen ST, Yu SY, Huang CY et al. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett 2000; 161: 171–175.
130. Yu LR, Lv JQ, Jin LY, Ding SD, Ma XY, Wang JJ et al. Over-expression of protein kinase Cisoforms (alpha, delta, theta and zeta) in squamous cervical cancer. Neoplasma 2011; 58: 491–498.
131. Kharait S, Dhir R, Lauffenburger D, Wells A. Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2006; 343: 848–856.
132. Villar J, Arenas MI, MacCarthy CM, Blanquez MJ, Tirado OM, Notario V. PCPH/ ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism. Cancer Res 2007; 67: 10859–10868.
133. McKiernan E, O’Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW et al. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer 2008; 99: 1644–1650.
134. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005; 55: 106–112.
135. Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS et al. DOG1 and PKC-theta are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011; 24: 866–875.
136. Kim KH, Nelson SD, Kim DH, Choi KU, Kim SJ, Min KW et al. Diagnostic relevance of overexpressions of PKC-theta and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases. Anticancer Res 2012; 32: 923–937.
137. Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J et al. Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1999; 59: 5710–5718.
138. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA et al. Protein kinase C delta is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res 2011; 71: 2087–2097.
139. Allen-Petersen BL, Carter CJ, Ohm AM, Reyland ME. Protein kinase Cdelta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 2013; 33: 1306–1315.
140. Mauro LV, Grossoni VC, Urtreger AJ, Yang C, Colombo LL, Morandi A et al. Bal de Kier Joffe, E.D. & Puricelli, L.L. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer. Pancreas 2010; 39: e31–e41.
141. Kim J, Koyanagi T, Mochly-Rosen D. PKCdelta activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate 2011; 71: 946–954.
142. Li N, Du ZX, Zong ZH, Liu BQ, Li C, Zhang Q et al. PKCdelta-mediated phosphorylation of BAG3 at Ser187 site induces epithelial-mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells. Oncogene 2012; 32: 4539–4548.
143. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-con-taining protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA 2011; 108: 1931–1936.
144. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010; 70: 5136–5146.
145. Sarkar S, Yong VW. Reduction of protein kinase C delta attenuates tenascin-C stimulated glioma invasion in three-dimensional matrix. Carcinogenesis 2010; 31: 311–317.
146. Jackson D, Zheng Y, Lyo D, Shen Y, Nakayama K, Nakayama KI et al. Suppression of cell migration by protein kinase Cdelta. Oncogene 2005; 24: 3067–3072.
147. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003; 1: 801–809.
148. Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S. Protein kinase C delta involvement in mammary tumor cell metastasis. Cancer Res 1999; 59: 3230–3238.
149. La Porta CA, Comolli R. Overexpression of nPKCdelta in BL6 murine melanoma cells enhances TGFbeta1 release into the plasma of metastasized animals. Melanoma Res 2000; 10: 527–534.
150. La Porta CA, Di Dio A, Porro D, Comolli R. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. Melanoma Res 2000; 10: 93–102.
151. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993; 8: 2095–2104.
152. Perletti GP, Folini M, Lin HC, Mischak H, Piccinini F, Tashjian Jr. AH. Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Oncogene 1996; 12: 847–854.
153. Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J et al. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol 1997; 17: 732–741.
154. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996; 13: 2517–2526.
155. Perletti GP, Concari P, Brusaferri S, Marras E, Piccinini F, Tashjian Jr. AH. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene 1998; 16: 3345–3348.
156. Hamilton M, Liao J, Cathcart MK, Wolfman A. Constitutive association of c-N-Ras with c-Raf-1 and protein kinase C epsilon in latent signaling modules. J Biol Chem 2001; 276: 29079–29090.
157. Cacace AM, Ueffing M, Han EK, Marme D, Weinstein IB. Overexpression of PKCepsilon in R6 fibroblasts causes increased production of active TGFbeta. J Cell Physiol 1998; 175: 314–322.
158. Cadoret A, Baron-Delage S, Bertrand F, Kornprost M, Groyer A, Gespach C et al. Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway. Oncogene 1998; 17: 877–887.
159. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999; 154: 137–144.
160. Brenner W, Farber G, Herget T, Wiesner C, Hengstler JG, Thuroff JW. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anticancer Res 2003; 23: 4001–4006.
161. Krasnitsky E, Baumfeld Y, Freedman J, Sion-Vardy N, Ariad S, Novack V et al. PKCeta is a novel prognostic marker in non-small cell lung cancer. Anticancer Res 2012; 32: 1507–1513.
162. Lu HC, Chou FP, Yeh KT, Chang YS, Hsu NC, Chang JG. Expression of protein kinase C family in human hepatocellular carcinoma. Pathol Oncol Res 2010; 16: 385–391.
163. Black JD. Protein kinase C-mediated regulation of the cell cycle. Front Bio 2000; 5: D406–D423.
164. Gorin MA, Pan Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Mol Cancer 2009; 8: 9.
165. Fishman DD, Segal S, Livneh E. The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int J Oncol 1998; 12: 181–186.
166. Basu A, Sivaprasad U. Protein kinase Cepsilon makes the life and death decision. Cell Signal 2007; 19: 1633–1642.
167. McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW et al. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003; 22: 7958–7968.
168. Okhrimenko H, Lu W, Xiang C, Hamburger N, Kazimirsky G, Brodie C. Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res 2005; 65: 7301–7309.
169. Lu D, Huang J, Basu A. Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem 2006; 281: 22799–22807.
170. Meshki J, Caino MC, von Burstin VA, Griner E, Kazanietz MG. Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J Biol Chem 2010; 285: 26033–26040.
171. Gonzalez-Guerrico AM, Meshki J, Xiao L, Benavides F, Conti CJ, Kazanietz MG. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol 2005; 38: 639–645.
172. Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal 2011; 23: 1348–1357.
173. Felber M, Sonnemann J, Beck JF. Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells. Pathol Oncol Res 2007; 13: 295–301.
174. Lu D, Sivaprasad U, Huang J, Shankar E, Morrow S, Basu A. Protein kinase C-epsilon protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis 2007; 12: 1893–1900.
175. Caino MC, Lopez-Haber C, Kim J, Mochly-Rosen D, Kazanietz MG. Proteins kinase Cvarepsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene 2012; 31: 2593–2600.
176. Garg R, Blando J, Perez CJ, Wang H, Benavides FJ, Kazanietz MG. Activation of Nuclear Factor kappaB (NF-kappaB) in Prostate Cancer Is Mediated by Protein Kinase C {epsilon} (PKC{epsilon}). J Biol Chem 2012; 287: 37570–37582.
177. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62: 2423–2429.
178. Hafeez BB, Zhong W, Weichert J, Dreckschmidt NE, Jamal MS, Verma AK. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011; 71: 2318–2327.
179. Huang B, Cao K, Li X, Guo S, Mao X, Wang Z et al. The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011; 30: 88.
180. Akita Y. Protein kinase Cepsilon: multiple roles in the function of, and signaling mediated by, the cytoskeleton. FEBS J 2008; 275: 3995–4004.
181. Akita Y. Protein kinase C-epsilon (PKC-epsilon): its unique structure and function. J Biochem 2002; 132: 847–852.
182. Prekeris R, Mayhew MW, Cooper JB, Terrian DM. Identification and localization of an actin-binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. J Cell Biol 1996; 132: 77–90.
183. Hernandez RM, Wescott GG, Mayhew MW, McJilton MA, Terrian DM. Biochemical and morphogenic effects of the interaction between protein kinase C-epsilon and actin in vitro and in cultured NIH3T3 cells. J Cell Biochem 2001; 83: 532–546.
184. Tachado SD, Mayhew MW, Wescott GG, Foreman TL, Goodwin CD, McJilton MA et al. Regulation of tumor invasion and metastasis in protein kinase C epsilon-transformed NIH3T3 fibroblasts. J Cell Biochem 2002; 85: 785–797.
185. Besson A, Davy A, Robbins SM, Yong VW. Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 2001; 20: 7398–7407.
186. Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004; 23: 8659–8672.
187. Pan Q, Bao LW, Teknos TN, Merajver SD. Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res 2006; 66: 9379–9384.
188. Caino MC, Lopez-Haber C, Kissil JL, Kazanietz MG. Non-small cell lung carcinoma cell motility, rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS One 2012; 7: e31714.
189. Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK. Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res 2001; 61: 808–812.
190. Wheeler DL, Martin KE, Ness KJ, Li Y, Dreckschmidt NE, Wartman M et al. Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. Cancer Res 2004; 64: 7756–7765.
191. Sand JM, Aziz MH, Dreckschmidt NE, Havighurst TC, Kim K, Oberley TD et al. PKCepsilon overexpression, irrespective of genetic background, sensitizes skin to UVR-induced development of squamous-cell carcinomas. J Invest Dermatol 2010; 130: 270–277.
192. Wheeler DL, Reddig PJ, Ness KJ, Leith CP, Oberley TD, Verma AK. Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease. Am J Pathol 2005; 166: 117–126.
193. Bao L, Gorin MA, Zhang M, Ventura AC, Pomerantz WC, Merajver SD et al. Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer. Cancer Res 2009; 69: 5829–5834.
194. Dann SG, Golas J, Miranda M, Shi C, Wu J, Jin G et al. p120 catenin is a key effector of a Ras-PKCvarepsilon oncogenic signaling axis. Oncogene 2013; 33: 1385–1394.
195. Selbie LA, Schmitz-Peiffer C, Sheng Y, Biden TJ. Molecular cloning and characterization of PKC iota, an atypical isoform of protein kinase C derived from insulin-secreting cells. J Biol Chem 1993; 268: 24296–24302.
196. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties. Proc Natl Acad Sci USA 1989; 86: 3099–3103.
197. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 2007; 9: 443–454.
198. Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA et al. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 2005; 19: 243–245.
199. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040–4048.
200. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778–789.
201. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37: 382–390.
202. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006; 354: 2431–2442.
203. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9: 287–300.
204. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005; 65: 11335–11344.
205. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001; 61: 6885–6891.
206. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65: 8679–8689.
207. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790–13795.
208. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn Jr PA et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005; 167: 1763–1775.
209. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol 2009; 29: 104–115.
210. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003; 3: 31.
211. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234–7242.
212. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005; 24: 6626–6636.
213. Mustafi R, Cerda S, Chumsangsri A, Fichera A, Bissonnette M. Protein kinase-zeta inhibits collagen I-dependent and anchorage-independent growth and enhances apoptosis of human Caco-2 cells. Mol Cancer Res 2006; 4: 683–694.
214. Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, Sehouli J et al. Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res 2010; 8: 919–934.
215. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res 2002; 62: 2630–2636.
216. Filomenko R, Poirson-Bichat F, Billerey C, Belon JP, Garrido C, Solary E et al. Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. Cancer Res 2002; 62: 1815–1821.
217. Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrezou JP, Laurent G et al. Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol 2002; 62: 1446–1455.
218. Cataldi A, Centurione L, Di Pietro R, Rapino M, Bosco D, Grifone G et al. Protein kinase C zeta nuclear translocation mediates the occurrence of radioresistance in friend erythroleukemia cells. J Cell Biochem 2003; 88: 144–151.
219. Xin M, Gao F, May WS, Flagg T, Deng X. Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation. J Biol Chem 2007; 282: 21268–21277.
220. Rimessi A, Zecchini E, Siviero R, Giorgi C, Leo S, Rizzuto R et al. The selective inhibition of nuclear PKCzeta restores the effectiveness of chemotherapeutic agents in chemoresistant cells. Cell cycle 2012; 11: 1040–1048.
221. Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T et al. c-Myc phosphorylation by PKCzeta represses prostate tumorigenesis. Proc Natl Acad Sci USA 2013; 110: 6418–6423.
222. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF et al. Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. Cell 2013; 152: 599–611.
223. Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627–4635.
224. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 12519–12524.
225. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67: 3074–3084.
226. Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. J Biol Chem 2004; 279: 9400–9408.
227. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D et al. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164: 797–802.
228. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010; 70: 2064–2074.
229. Murray NR, Kalari KR, Fields AP. Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer. J Cell Physiol 2011; 226: 879–887.
230. Frederick LA, Matthews JA, Jamieson L, Justilien V, Thompson EA, Radisky DC et al. Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer. Oncogene 2008; 27: 4841–4853.
231. Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, Fields AP. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009; 69: 7603–7611.
232. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280: 31109–31115.
233. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905–8911.
234. Justilien V, Jameison L, Der CJ, Rossman KL, Fields AP. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J Biol Chem 2011; 286: 8149–8157.
235. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 2008; 68: 5888–5895.
236. Sengupta A, Duran A, Ishikawa E, Florian MC, Dunn SK, Ficker AM et al. Atypical protein kinase C (aPKCzeta and aPKClambda) is dispensable for mammalian hematopoietic stem cell activity and blood formation. Proc Natl Acad Sci USA 2011; 108: 9957–9962.
237. Atwood SX, Li M, Lee A, Tang JY, Oro AE. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature 2013; 494: 484–488.
238. Baldwin RM, Parolin DA, Lorimer IA. Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene 2008; 27: 3587–3595.
239. Win HY, Acevedo-Duncan M. Atypical protein kinase C phosphorylates IKKal-phabeta in transformed non-malignant and malignant prostate cell survival. Cancer Lett 2008; 270: 302–311.
240. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y et al. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009; 106: 16369–16374.
241. Liu SG, Wang BS, Jiang YY, Zhang TT, Shi ZZ, Yang Y et al. Atypical protein kinase Ciota (PKCiota) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCiota-SKP2-AKT pathway. Mol Cancer Res 2011; 9: 390–402.
242. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012; 11: 937–957.
243. Barry OP, Kazanietz MG. Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001; 7: 1725–1744.
244. Kazanietz MG, Lewin NE, Gao F, Pettit GR, Blumberg PM. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol 1994; 46: 374–379.